Portola's Rocky Commercial Transition On Show In Q2, With No CEO
Executive Summary
Company reported only $33,000 in sales for late anticoagulant market entrant Bevyxxa and $2.2m for the antidote Andexxa, leaving a lot of challenges ahead after the retirement of CEO Bill Lis, effective Aug. 1.
You may also be interested in...
PhaseBio’s Bentracimab Could Benefit From Growth In Brilinta Demand
The antiplatelet drug-reversal agent could see uptake grow in tandem with that of Brilinta, but there is a history of drugs in similar indications underperforming on the market.
Garland Takes Helm Of Portola At A Crucial Time
Portola touts exec's commercial management experience with Genentech success stories Avastin and Tarceva.
Keeping Track: J&J Esketamine, Sanofi Caplacizumab Lead Off September Submissions; US FDA Says No To Nucala
The latest drug development news and highlights from our US FDA Performance Tracker.